These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26824277)

  • 1. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
    Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
    Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
    Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
    Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
    Fiorucci S; Mencarelli A; Palladino G; Cipriani S
    Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.
    Sepe V; Distrutti E; Limongelli V; Fiorucci S; Zampella A
    Future Med Chem; 2015; 7(9):1109-35. PubMed ID: 26132522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
    Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
    J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acid receptors in non-alcoholic fatty liver disease.
    Li Y; Jadhav K; Zhang Y
    Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
    De Marino S; Festa C; Sepe V; Zampella A
    Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
    Festa C; Renga B; D'Amore C; Sepe V; Finamore C; De Marino S; Carino A; Cipriani S; Monti MC; Zampella A; Fiorucci S
    J Med Chem; 2014 Oct; 57(20):8477-95. PubMed ID: 25247751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
    Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
    Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
    Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation.
    Miyazaki-Anzai S; Masuda M; Kohno S; Levi M; Shiozaki Y; Keenan AL; Miyazaki M
    J Lipid Res; 2018 Sep; 59(9):1709-1713. PubMed ID: 29976576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
    J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
    Pellicciari R; Sato H; Gioiello A; Costantino G; Macchiarulo A; Sadeghpour BM; Giorgi G; Schoonjans K; Auwerx J
    J Med Chem; 2007 Sep; 50(18):4265-8. PubMed ID: 17685603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5.
    Trammell SAJ; Svenningsen JS; Holst JJ; Gillum MP; Kuhre RE
    Molecules; 2020 May; 25(10):. PubMed ID: 32443832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
    Sindhu T; Srinivasan P
    Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR.
    Ay Ü; Leníček M; Haider RS; Classen A; van Eijk H; Koelfat KVK; van der Kroft G; Neumann UP; Hoffmann C; Bolm C; Olde Damink SWM; Schaap FG
    Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38517202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.